Maria Ramirez
Stage IB2 cervical carcinoma, squamous cell type, HPV-positive. Maria was referred following an abnormal cervical smear result and subsequent colposcopic biopsy confirming invasive squamous cell carcinoma. MRI staging demonstrated a 4.2 cm primary tumour confined to the cervix with no parametrial involvement or pelvic lymphadenopathy. She was treated with definitive concurrent chemoradiation — external beam radiotherapy with weekly cisplatin chemosensitisation, followed by brachytherapy — in accordance with international guidelines for locally advanced cervical cancer.
Maria Ramirez was thirty-nine and in perfect health — or so she believed — when a smear test result changed everything. The abnormal report led to a colposcopy, then a biopsy, then the phone call she had been dreading. Cervical cancer, stage IB2. She sat in her car in the hospital car park for a long time after that call, unable to drive. She had two children aged seven and ten, a job she loved, a life that had felt utterly solid an hour before. That evening, she told her family. The following week, she had her first appointment at Silvaris Cancer Institute in San Diego.
The gynaecological oncologist who became Maria's lead clinician was direct, warm, and extraordinarily thorough. She explained that the tumour, while significant in size, had not spread beyond the cervix — a crucial finding that made curative treatment possible. The proposed treatment was chemoradiation: a combination of daily radiotherapy and weekly chemotherapy, followed by internal radiotherapy known as brachytherapy. "She drew me a diagram," Maria says. "She explained exactly how the radiation would target the tumour while protecting surrounding tissue, and why the chemotherapy made the radiotherapy more effective. I didn't understand everything that day, but I left knowing that the plan was intelligent and that she believed in it."
Treatment lasted seven weeks. Daily trips to the radiotherapy suite became routine, though not painless — fatigue accumulated over the weeks, and the bowel and bladder side effects were uncomfortable and at times distressing. The specialist oncology nursing team provided detailed written guidance on managing each side effect and ran a weekly drop-in clinic for patients on treatment. Maria attended every week. "Those nurses knew what I was going through better than anyone," she says. "They had seen it all before. They never dismissed what I was feeling, and they always had something practical to offer." The brachytherapy sessions, though daunting, were manageable with effective pain relief.
Three months after completing treatment, an MRI scan showed complete radiological response — the tumour was no longer visible. Maria's oncologist shared the result at the end of a clinic appointment, and both of them cried. "That moment is burned into my memory," Maria says. "She had fought for me as hard as I had fought for myself." A structured follow-up programme of six-monthly clinical examinations and annual imaging began. Fertility was not preserved — a loss that Maria grieved, having hoped for a third child — but her oncologist had taken time before treatment began to discuss this openly and refer her to a counsellor who specialised in oncological fertility grief.
Four years after her diagnosis, Maria's surveillance scans remain clear. She has returned fully to work, resumed her active social life, and taken up running — something she had never done before cancer. She now participates in a peer support programme at the cancer institute, talking to newly diagnosed patients about life during and after treatment. "I remember being that terrified woman in the car park," she says. "I want other women to know that treatment is hard but survivable, and that the team at Silvaris will carry you when you can't carry yourself. They carried me. Now I try to carry others."
